ELABELA concentration is not decreased in maternal plasma before the onset of preeclampsia

Villié, Patricia; Lefèvre, Guillaume; Arrestier, Romain; Rousseau, Alexandra; Berkane, Nadia; Hertig, Alexandre

doi:10.1016/j.ajog.2018.12.020

Cited by 16 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the ELABELA plasma levels noted in late-onset preeclampsia were also increased compared with those determined in women with early-onset preeclampsia [21]. In line with previous reports, Villie et al did not detect any alterations in circulating ELABELA plasma levels between women who developed preeclampsia and gestational age-matched controls at ~25 weeks' gestation [22]. Para et al reported that patients with late-onset preeclampsia, but not those with early-onset preeclampsia, had increased ELABELA blood levels compared with the members of the age-matched control groups [23].…”

Section: Elabela Secretion In Uncomplicated Pregnancies and Pregnancy...supporting

confidence: 83%

ELABELA as a Marker of Gestational Complications – A Review

Sibiak

2022

Medical Journal of Cell Biology

View full text Add to dashboard Cite

Adipose tissue secretes dozens of biologically active molecules known as adipokines or adipocytokines. Apelin receptor early endogenous ligand (ELABELA, also known as ELA or APELA) is a circulating signaling protein expressed in placental tissue that binds to apelin receptors. The first animal experimental findings suggested that the ELABELA deficiency might be responsible for the pathogenesis of preeclampsia--like symptoms, i.e., hypertension and proteinuria in mice. Exogenous ELABELA supplementation reverted preeclampsia symptoms and normalized fetal birth weight in mice. Several in vitro studies confirmed that ELABELA supplementation could improve trophoblast cell functions such as invasiveness and proliferation capacity. Thus, the ELABELA axis could serve as the target of innovative therapies for gestational complications. Nonetheless, most human studies do not support the thesis that disturbances in ELABELA secretion in early pregnancy are associated with an increased risk of preeclampsia. Therefore, it is unlikely that ELABELA could serve as a novel early marker of preeclampsia in humans. Alterations in the ELABELA secretion have also been discovered among patients with other gestational complications such as GDM and fetal growth restriction.

show abstract

Section: Elabela Secretion In Uncomplicated Pregnancies and Pregnancy...supporting

confidence: 83%

ELABELA as a Marker of Gestational Complications – A Review

Sibiak

2022

Medical Journal of Cell Biology

View full text Add to dashboard Cite

show abstract

“…In line with our findings, four recent reports drew a similar conclusion in human. First, Villie et al [ 17 ] investigated circulating ELA levels before PE onset (mean gestation age at sampling was about 24 weeks) and indicated that ELA concentrations did not differ between 12 PE patients and 14 controls (mean was 11.86 ± 10.8 versus 8.71 ± 7.7 ng/mL). Second, Pritchard et al [ 18 ] found no difference of circulating ELA concentrations (gestation age at sampling ranged from 26.7 weeks to 30.9 weeks) between 32 women with preterm PE and 32 matched controls (median, 28.5 pg/mL; 95% CI, 5.3 to 63.2 versus median, 20.5 pg/mL; 95% CI, 9.2 to 58.0, respectively); moreover, placental mRNA (encoding ELA) was unchanged in 82 PE patients compared with 82 matched healthy controls (mean difference, 0.53%; 95% CI, -25.9 to 27.0; P = 0.78).…”

Section: Discussionmentioning

confidence: 99%

Association between ELABELA Serum Concentrations in First Trimester and Pregnancy-Induced Hypertension

Guo

Zhang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

ELABELA (ELA) is considered to be implicated in the pathophysiology of preeclampsia (PE), since ELA-deficient mice exhibited PE-like symptoms and infusion of exogenous ELA normalized the gestational hypertension (GH) and proteinuria. However, no evidence show that circulating ELA is deficient in early placental development among women who destined to develop GH/PE. This nested case-control study was conducted to investigate the association between serum ELA concentration in early pregnancy and the risk of later GH/PE. Participants were recruited and sampled in 10-14+6 weeks of gestation. Definite GH/PE cases were matched 1 : 3 to controls with respect to age and gestational age. Serum concentration of ELA was measured using enzyme immunoassay. Women with later GH ( N = 28 ) had a slightly lower median concentration of ELA (46.72 ng/mL versus 53.54 ng/mL), while those with later PE ( N = 16 ) had a slightly higher median concentration of ELA (74.8 ng/mL versus 66.30 ng/mL) compared to the controls. Yet, both the increments did not reach statistically significant difference (GH: P = 0.380 , PE: P = 0.799 ). ELA serum concentrations were unchanged in first trimester in women with GH/PE. Further studies are still needed to identify the dynamic changes in serum ELA concentrations during the whole pregnancy, especially in those with pregnancy-induced hypertensive disorders.

show abstract

“…In umbilical arteries and veins of newborns, Elabela concentration was also decreased [13]. Whereas, Pritchard et al [14] and Villie et al [15] found the levels of placenta and plasma Elabela in preeclampsia patients had no difference with those of normal pregnant women.…”

Section: Introductionmentioning

confidence: 94%

Maternal Plasma Elabela, a Biomarker for the Severity and Kidney Function of Human Preeclampsia

Ma¹,

Hou²,

Wu³

et al. 2022

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: It reported that serum Elabela level was decreased in preeclampsia patients. However, there is no researcher done the study on the correlations between plasma Elabela and kidney function, blood pressure, blood glucose and lipid in preeclampsia patients. Our objective is determined whether plasma Elabela could be a marker for the severity and kidney function of preeclampsia. Methods: 72 pregnant women were enrolled in this study and divided into healthy group (n = 37), mild preeclampsia group (n = 20) and severe preeclampsia group (n = 15). The level of plasma Elabela was detected using ELISA. Results: Plasma Elabela was reduced in preeclampsia patients compared to healthy group, and severe preeclampsia patients had the lower level of Elabela and poorer kidney function. The level of plasma Elabela was negatively correlated with those of uric acid (UA), creatinine (Cre), cystatin C (CysC), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Conclusions: Lower concentration of plasma Elabela correlated with worse kidney function, and higher blood pressures in preeclampsia patients.

show abstract

ELABELA concentration is not decreased in maternal plasma before the onset of preeclampsia

Cited by 16 publications

References 3 publications

ELABELA as a Marker of Gestational Complications – A Review

ELABELA as a Marker of Gestational Complications – A Review

Association between ELABELA Serum Concentrations in First Trimester and Pregnancy-Induced Hypertension

Maternal Plasma Elabela, a Biomarker for the Severity and Kidney Function of Human Preeclampsia

Contact Info

Product

Resources

About